Market Place
Sourcing Support
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
06 Jun 2023 //
FIERCE PHARMA
With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M
08 Apr 2023 //
FIERCE PHARMA
Clovis reveals even more regulatory troubles for Rubraca
13 Feb 2023 //
FIERCE PHARMA
Embattled Clovis Oncology Files for bankruptcy, Sells pipeline asset to Novartis
13 Dec 2022 //
BIOSPACE
Clovis Oncology Enters into Agreement to Sell FAP-2286
12 Dec 2022 //
BUSINESSWIRE
Cancer drugmaker Clovis files for bankruptcy, hit by falling sales
12 Dec 2022 //
REUTERS
Clovis` Rubraca Receives Approval in Europe
08 Dec 2022 //
EMA
Loan default, Rubraca move inches Clovis closer to bankruptcy
06 Dec 2022 //
FIERCEPHARMA
After GSK, FDA asks Clovis to restrict PARP drug`s cancer use
18 Nov 2022 //
FIERCEPHARMA
Cancer drugmaker Clovis flags possible bankruptcy
10 Nov 2022 //
REUTERS
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca
27 Oct 2022 //
BUSINESSWIRE
Clovis Highlights Updated LuMIERE PhI Data of FAP-2286
17 Oct 2022 //
BUSINESSWIRE
Pfizer, Clovis Make Inroads Against Tough to Treat Prostate Cancer
05 Oct 2022 //
BIOSPACE
Clovis trots out Rubraca prostate cancer partial win
04 Oct 2022 //
FIERCEPHARMA
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
21 Sep 2022 //
BUSINESSWIRE
Clovis files for Rubraca expansion despite FDA warning
14 Sep 2022 //
FIERCEPHARMA
Clovis Oncology Submits Applications for Rubraca Label Expansion
13 Sep 2022 //
BUSINESSWIRE
Clovis Oncology’s Rubraca Improves Progression-Free Survival in Women
11 Sep 2022 //
BUSINESSWIRE
Clovis needs cash now to stem looming financial challenges
08 Aug 2022 //
FIERCEBIOTECH
Clovis Oncology Announces Second Quarter 2022 Operating Results
08 Aug 2022 //
BUSINESS WIRE
CORRECTING and REPLACING Clovis Oncology to Announce Q2 2022 Financial Results
20 Jul 2022 //
BUSINESSWIRE
Clovis pulls Rubraca in 3L ovarian cancer amid death risk fears
18 Jun 2022 //
FIERCEPHARMA
Clovis Oncology Highlights PI Data from Ongoing Studies of FAP-2286 at SNMMI
14 Jun 2022 //
BUSINESSWIRE
Clovis Oncology’s Rubraca as 1L Maintenance Treatment in Ovarian Cancer
06 Jun 2022 //
BUSINESSWIRE
Clovis unveils crippling FDA delay as its troubles deepen
07 May 2022 //
FIERCEPHARMA
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
05 May 2022 //
BUSINESSWIRE
Clovis Oncology Announces Q1 2022 Operating Results and Provides Clinical Update
04 May 2022 //
BUSINESSWIRE
Clovis Oncology Highlights Rubraca and FAP-2286 Data to be Presented at ASCO
28 Apr 2022 //
BUSINESSWIRE
Clovis Oncology to Announce Q1 2022 Financial Results
20 Apr 2022 //
BUSINESSWIRE
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca at AACR
08 Apr 2022 //
BUSINESSWIRE
Clovis Oncology’s Rubraca Improves Progression-Free Survival in Ovarian Cancer
31 Mar 2022 //
BUSINESSWIRE
Clovis Oncology and Evergreen Theragnostics Initiate Agreement for FAP-2286
16 Mar 2022 //
BUSINESSWIRE
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study of FAP-2286
25 Feb 2022 //
BUSINESSWIRE
Clovis Oncology Announces 2021 Operating Results, Anticipated 2022 Milestones
23 Feb 2022 //
BUSINESSWIRE
Clovis Oncology Highlights FAP-2286 Preclinical Data at TRS 2021
09 Dec 2021 //
BUSINESSWIRE
Top 10 drug launch disasters
25 Oct 2021 //
FIERCEPHARMA
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
19 Oct 2021 //
BUSINESSWIRE
Pan-Cancer Analysis Suggests FAP for Peptide-Targeted Radionuclide Therapy
07 Oct 2021 //
BUSINESSWIRE
Clovis Oncology Announces Availability of and Reimbursement for Rubraca®
24 Aug 2021 //
BUSINESSWIRE
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
16 Aug 2021 //
BUSINESSWIRE
Clovis Oncology Announces Second Quarter 2021 Operating Results
04 Aug 2021 //
BUSINESSWIRE
Clovis Oncology to Announce Second Quarter 2021 Financial Results
21 Jul 2021 //
BUSINESSWIRE
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
12 Jul 2021 //
BUSINESSWIRE
FAP-2286 in Independent Named Patient Use Published
28 Jun 2021 //
BUSINESSWIRE
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating FAP-2286
23 Jun 2021 //
BUSINESSWIRE
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
10 Jun 2021 //
BUSINESSWIRE
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO
18 May 2021 //
BUSINESSWIRE
Clovis spikes ovarian cancer combo after `underwhelming` efficacy; Servier
05 May 2021 //
ENDPTS
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free
19 Mar 2021 //
BUSINESSWIRE
Clovis Oncology seeks US FDA nod to initiate ph 1/2 study lutetium-177 FAP-2286
31 Dec 2020 //
PHARMABIZ
Clovis Oncology Submits Investigational New Drug Applications
29 Dec 2020 //
BUSINESSWIRE
Clovis Oncology sNDA for Novel Peptide-Targeted Radionuclide FAP-2286
29 Dec 2020 //
BUSINESSWIRE
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly
21 Dec 2020 //
BUSINESSWIRE
Clovis Oncology Announces Oral Plenary Session Presentation At IGCS Global Meet
10 Sep 2020 //
PRESS RELEASE
Journal of Clinical Oncology Publishes Additional Data from Clovis Rubraca®
17 Aug 2020 //
BUSINESSWIRE
Clovis Oncology Announces First Patient Enrolled In The Ph2 Portion The LIO-1
05 Aug 2020 //
PRESS RELEASE
Clovis Oncology Announces First Patient Enrolled in the Ph2 Portion the LIO-1
04 Aug 2020 //
BUSINESSWIRE
Clovis Oncology to Highlight Rubraca®& Lucitanib Non-Clinical Data at the AACR
17 Jun 2020 //
BUSINESSWIRE
Clovis Oncology Announces Completion of Target in the ATHENA Trial, a Ph3
10 Jun 2020 //
PRESS RELEASE
Clovis Oncology Announces New Recommendations For Rubraca® (Rucaparib)
28 May 2020 //
PRESS RELEASE
